2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BispecificAntigens, NeoplasmAntineoplastic AgentsAscitic FluidCarcinoma, PapillaryCD3 ComplexCD4-Positive T-LymphocytesCell Adhesion MoleculesCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesCytokinesCytotoxicity, ImmunologicEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansLymphocyte ActivationNeoplasms, Cystic, Mucinous, and SerousT-Lymphocytes, CytotoxicUterine NeoplasmsConceptsUterine serous carcinoma cell linesUterine serous carcinomaEpithelial cell adhesion moleculeCell adhesion molecule expressionCarcinoma cell linesChromium release assaysSerous carcinoma cellsPeripheral blood lymphocytesAdhesion molecule expressionCell adhesion moleculeEpithelial cell adhesion molecule (EpCAM) expressionSerous carcinomaAdhesion moleculesBlood lymphocytesMolecule expressionT cellsAscitic fluidCell linesTumor-associated T cellsT cell-mediated killingT-cell activation markersFlow cytometryTumor cellsCarcinoma cellsRobust immunologic responses
2011
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation
Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.Peer-Reviewed Original ResearchConceptsCervical carcinoma cellsCervical cancer cellsHuman papillomavirus E6Human cervical carcinoma cellsCarcinoma cellsPrimary cervical cancer cellsCancer cellsPapillomavirus E6Cervical carcinoma cell linesE2 proteinHuman cervical cancer cellsCarcinoma cell linesE7 expressionE7 oncogenesLow passage numberSerum-free conditionsCell surface receptorsSV40 infectionTumor suppressor pathwayCell linesPrimary cellsViral vectorsE6Suppressor pathwayPassage number
1996
Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules
Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.Peer-Reviewed Original ResearchConceptsIL-2Interleukin-2Ovarian carcinoma cellsOvarian cancerAllogeneic peripheral blood lymphocytesAdvanced epithelial ovarian cancerBALB/c nude miceChromium-51 release assaysMajor histocompatibility complex class IAdvance ovarian cancerCarcinoma cellsHistocompatibility complex class IEpithelial ovarian cancerMajor histocompatibility complex moleculesPeripheral blood lymphocytesHuman ovarian carcinoma cell linesHuman ovarian carcinoma cellsOvarian carcinoma cell linesComplex class ICytokine interleukin-2Long-term cytotoxicHistocompatibility complex moleculesMonths of studyUCI-107Tumor vaccines